UC - Ulcerative Colitis
9
3
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
Impact of Therapeutic Intervention on Quality of Life in Patients With Ulcerative Colitis
Enabling Microbiomics- Driven Personalized Nutrition
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
Low FODMAP Diet on Nutritional Status, Disease Activity and Gut Microbiota in IBS and UC With Normal or Overweight BMI